Persistent villous atrophy despite a 'gluten-free' diet
A 34-year-old woman with coeliac disease diagnosed 2 years ago is referred because of ongoing diarrhoea, fatigue, and iron-deficiency anaemia. Duodenal biopsy still shows villous atrophy, and tTG-IgA remains four times the upper limit of normal. She reports strict adherence: she buys only products labelled 'gluten-free', avoids all foods with 'may contain wheat', drinks two gluten-free beers each week, and eats gluten-free oats daily. She also takes a 'gluten-free' multivitamin. She lives in an EU country, eats out once a week, and uses a shared toaster at her partner's home. She asks whether she needs a stronger probiotic or whether her disease is simply refractory. Ferritin is 9 µg/L, and she has lost 3 kg unintentionally.
1. How would you interpret the label claims and identify the most likely sources of ongoing gluten exposure?
Read the worked answer
In the EU, a 'gluten-free' claim means the food contains no more than 20 mg/kg gluten; it does not mean the food is guaranteed free of all traces or that every 'gluten-free' product is suitable for every coeliac patient. The likely issues are not the label claim itself but cross-contact and product type. Shared toasters and shared utensils are common sources of contamination. Gluten-free beer may be made from barley or wheat and treated to reduce gluten; it can meet the <20 mg/kg claim but still be a risk for some patients, especially with daily exposure. Oats are naturally gluten-free but are frequently contaminated with wheat, barley, or rye; only specially processed, uncontaminated oats should be used, and some coeliac patients tolerate them poorly. The multivitamin is unlikely to be the main cause but should be checked. 'May contain' is advisory and does not prove the product contains gluten; avoiding all such products does not explain persistent villous atrophy. The judgement is to investigate cross-contact, oats, beer, and eating out before labelling the disease refractory.
2. What practical advice and further assessment would you provide?
Read the worked answer
Advise a structured gluten-exposure review: keep a detailed 2–4 week food, drink, supplement, and eating-out diary; stop the gluten-free beer and all oats temporarily, then reintroduce only certified uncontaminated oats if tolerated; use a dedicated toaster, colander, and utensils; ask restaurants about separate preparation and avoid shared fryers, sauces, and breaded foods. Check the multivitamin and any other supplements with the manufacturer. Do not simply add a probiotic; there is no reliable evidence that it corrects ongoing gluten exposure. Assess for other causes of villous atrophy and persistent symptoms with the gastroenterologist: medication review, thyroid disease, inflammatory bowel disease, small intestinal bacterial overgrowth, pancreatic insufficiency, and, if exposure is excluded, refractory coeliac disease. Monitor tTG-IgA, ferritin, haemoglobin, folate, vitamin B12, vitamin D, calcium, and weight. Arrange dietitian follow-up and consider a repeat biopsy only as directed by the gastroenterologist. Document the exposure review and the plan to reassess before escalating therapy.
3. The patient asks whether she should avoid all 'may contain' foods and whether a gluten-free label is enough. How do you answer?
Read the worked answer
Explain that 'may contain' is a precautionary advisory, not a regulated declaration that gluten is present. Avoiding every such product can make the diet unnecessarily restrictive and does not address the likely cross-contact sources in her kitchen and eating-out routine. A 'gluten-free' label is a useful legal guarantee at the 20 mg/kg level, but it is not a guarantee against cross-contact after purchase. The label is necessary but not sufficient: she still needs to manage shared equipment, restaurants, and products such as beer and oats. Avoid blaming her adherence; instead, frame the plan as finding hidden exposure. Give her specific questions to ask manufacturers and restaurants, and offer written information. Reassess symptoms, tTG-IgA, and ferritin after the exposure trial. If symptoms persist despite documented adherence and exposure control, refer back to gastroenterology for evaluation of refractory coeliac disease.